Strata Critical Medical, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Strata Critical Medical, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2019
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
31.2
23.4
50.5
146
225
147
197
Cost of revenue
26.5
21.1
40
124
183
117
156
Gross profit
4.7
2.33
10.5
22.3
42.1
29.6
41.1
Selling, general and administrative
50.9
60.9
Selling and marketing
5.01
2.53
2.79
7.75
10.4
7.95
General and administrative
10.5
9.29
30.1
62.5
95.2
81.7
Operating expenses
0.68
-24.9
-36.6
-33.2
52.1
63.5
Operating income
-11.5
-10.4
-0.68
-24.1
-53.5
-68.1
-22.5
-22.4
Other non-operating income
0.7
0.2
-19.6
25.5
10.6
6.36
2.29
Pre-tax income
-10.8
-10.2
-20.3
-43.7
-28
-57.5
-16.2
-20.1
Income tax
0
0.21
0
0.21
-3.64
-0.77
-1.47
0
0
Income from continuing operations
-16.2
-20.1
Net income
-10.8
2.33
-10.2
-20.5
-40.1
-27.3
-56.1
-27.3
41.3
EBITDA
-11.1
-9.83
-23.5
-47.8
-61
-16.6
-14.2
EPS, basic
-0.43
0.19
-0.40
-2.17
-0.93
-0.38
-0.76
-0.35
0.50
EPS, diluted
-0.43
0.19
-0.40
-2.17
-0.93
-0.38
-0.76
-0.35
0.50
Shares, basic (weighted)
25.1
8.03
25.2
9.69
42.9
71.2
73.5
77.5
82.1
Shares, diluted (weighted)
25.1
8.03
25.2
9.69
42.9
71.2
73.5
77.5
82.1
Balance sheet
FY2020
FY2019
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
22.2
1.31
12.2
0.85
6.95
41.3
27.9
18.4
31
Short-term investments
0
297
151
138
109
30.3
Receivables
1.09
3.77
10.9
21
19.8
40
Other current assets
0.13
1.01
0.05
5.93
12.1
18
0.51
5.01
Total current assets
1.43
14.4
0.9
314
218
206
161
126
Property, plant and equipment
1.76
1.96
2.04
2.9
28.5
36.4
Lease right-of-use assets
0.74
0.65
17.7
23.5
2.83
3.11
Goodwill
0
13.3
39.4
13.3
15.5
88.2
Intangible assets
0.53
12.6
46.4
20.5
7.96
47.5
Long-term investments
275
276
277
277
Other non-current assets
0.11
0.22
1.36
1.4
0.12
24
Total assets
277
278
17.7
278
343
325
295
257
325
Accounts payable
0.14
0.78
0.16
4.45
16.5
23.9
9.22
19.1
Accrued liabilities
0.04
0.14
Deferred revenue
3.97
4.65
6.71
6.85
6.66
Total current liabilities
0.35
0.37
6.34
0.39
9.53
26.6
35.5
22.7
19.8
Lease liabilities
0.29
0.22
15
19.7
2.34
2.66
Other non-current liabilities
0
22.1
Total liabilities
9.98
26.1
6.64
46.8
52.2
50.5
60.6
34.7
46.4
Total debt
0
Paid-in capital
5.2
2.67
48.2
23.2
369
376
390
407
425
Retained earnings
-0.21
2.33
-37.1
-18.2
-77.2
-104
-160
-187
-146
Other comprehensive income
0
-0.3
2.29
3.96
1.75
0
Shareholders' equity
20.7
5
11.1
10
291
274
234
222
279
Total equity
20.7
5
11.1
10
291
274
234
222
279
Total liabilities and equity
277
278
17.7
278
343
325
295
257
325
Cash flow statement
FY2020
FY2019
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-10.8
2.33
-10.2
-20.5
-40.1
-27.3
-56.1
-27.3
41.3
Depreciation and amortization
0.47
0.53
0.6
5.73
7.11
5.96
8.19
Stock-based compensation
0.32
0.49
9.62
8.28
12.5
19.9
17.8
Deferred income tax
0
0
-3.64
-0.77
-1.47
-0.26
0.43
Change in receivables
-0.17
-0.59
-0.41
-5.35
-10.3
-1
-12
Change in payables
-0.4
-1.41
0.02
1.96
9.9
9.05
-8.34
2.38
Cash from operations
-10.3
-10.8
-0.79
-15.6
-37.1
-32.3
-2.52
-48.9
Capital expenditures
-0.6
-0.38
-0.3
-0.73
-2.11
-30.9
-9.6
Acquisitions
0
0
-23.1
-48.1
0
-2.23
-66.5
Purchases of investments
0
0
-309
-0.73
-0.14
0
Sales and maturities of investments
0
0
11.3
258
20.5
0
70.2
Cash from investing
-1.05
-0.38
0.33
-321
79.3
17.1
-1.02
69.8
Stock issued
0.12
0.02
0.14
0.09
0.07
0.17
0.19
Share buybacks
0
-0.24
0
Cash from financing
0.12
1.18
332
-1.08
-0.08
-5.76
-8.91
Exchange rate effect
0
0.07
-0.07
-0.08
-0.34
Net change in cash
-11.2
-10
-0.46
-4.69
41.2
-15.4
-9.37
11.6
Free cash flow
-10.9
-11.2
-15.9
-37.9
-34.5
-33.4
-58.5
Interest paid
0
0
0.01
0
Income taxes paid
0
0
0.21
0
0
0.02
0
0.09
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.33 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
20.6%
Gross profit / revenue.
Operating margin
-8.0%
Operating income / revenue.
EBITDA margin
-4.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-9.0%
Pre-tax income / revenue.
Net margin
15.7%
Net income / revenue.
FCF margin
-18.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-14.1%
Cash from operations / revenue.
Return on equity (ROE)
14.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
12.1%
Net income / average total assets.
Return on invested capital (ROIC)
-6.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue
6.6%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
4.9%
Capital expenditures / revenue.
D&A / revenue
3.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
34.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
10.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
39.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
22.7%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
25.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
0.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
94.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
26.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
0.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
3.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
5.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
4.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
53.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.64x
Current assets / current liabilities.
Quick ratio
1.45x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.50x
(Cash + short-term investments) / current liabilities.
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.47
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.97
Revenue / diluted weighted shares.
FCF per share
-$0.56
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.42
Cash from operations / diluted weighted shares.
Book value per share
$3.24
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
11.7x
Market cap / net income. Only when net income is positive.
P/S
1.84x
Market cap / revenue.
P/B
1.69x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.20x
Market cap / tangible book value, when positive.
EV/Sales
1.75x
Enterprise value / revenue.
FCF yield
-10.3%
Free cash flow / market cap.
Earnings yield
8.5%
Net income / market cap (the inverse of P/E).
What was Strata Critical Medical, Inc.'s revenue in fiscal 2025?
Strata Critical Medical, Inc. reported revenue of $197.1M for fiscal 2025, 34.3% higher than the year before.
Was Strata Critical Medical, Inc. profitable in fiscal 2025?
Yes. Net income was $41.3M, a net margin of 21%.
How much free cash flow did Strata Critical Medical, Inc. generate in fiscal 2025?
Cash from operations of $48.9M minus capital expenditures of $9.6M left free cash flow of -$58.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.